Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina

Circulation

Volumn 89, Issue 2, 1994, Pages 596-603

  Simoons, Maarten L ^b   De Boer, Menko Jan ^a   Van Den Brand, Marcel J B M ^a   Van Miltenburg, Addy J M ^a   Hoorntje, Jan C A ^a   Heyndrickx, Guy R ^a   Van Der Wieken, L Ron ^a   De Bono, David ^a   Rutsch, Wolfgang ^a   Schaible, Thomas F ^a   Weisman, Harlan F ^a   Klootwijk, Peter ^a   Nijssen, Karin M ^a   Stibbe, Jeanne ^a   De Feyter, Pim J ^a  

^a Centocor ^*

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

angina; glycoproteins; platelets

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCERYL TRINITRATE; HEPARIN; IMMUNOGLOBULIN F(AB) FRAGMENT; NITRATE; PLACEBO; RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 23444458293     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.89.2.596     Document Type: Article

References (32)

1. Conti RC, Brawley RK, Griffith LSC, Pitt B, Humphries JO, Gott VL, Ross RS. Unstable angina pectoris: morbidity and mortality in 57 consecutive patients evaluated angiographically. Am J Cardiol. 1973;32:745-750.
2. Braunwald E. Unstable angina: a classification. Circulation. 1989; 80:410-414.
3. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation. 1988;77:1213-1220.
4. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 1989;63: 11AE-120E.
5. Forrester JS, Litvack F, Grundfest W, Hickey A. A perspective of coronary disease seen through the arteries of living man. Circulation. 1987;75:505-513.
6. The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomised, double blind placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both: the HINT Research Group. Br Heart J. 1986;56:400-413.
7. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, DeGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
8. Goldman BS, Katz A, Christakis G, Weisel R. Determinants of risk for coronary artery bypass grafting in stable and unstable angina pectoris. Can J Surg. 1985;28:505-508.
9. Myler RK, Shaw RE, Stertzer SH, Bashour TT, Ryan C, Hecht HS, Cumberland PC. Unstable angina and coronary angioplasty. Circulation. 1990;82(suppl II):II-88-II-95.
10. de Feyter PJ, Serruys PW, Suryapranata H, Beatt K, van den Brand M. Coronary angioplasty early after diagnosis of unstable angina. Am Heart J. 1987;114:48-54.
11. Cowley MJ, Dorros G, Kelsey SF, van Raden M, Detre KM. Acute coronary events associated with percutaneous transluminal coronary angioplasty. Am J Cardiol 1984;53:12C-16C.
12. van den Brand M, van Zijl A, Geuskens R, de Feyter PJ, Serruys PW, Simoons ML. Tissue plasminogen activator in refractory unstable angina: a randomized double blind placebo controlled trial in patients with refractory unstable angina and subsequent angioplasty. Eur Heart J. 1991;12:1208-1214.
13. Nicklas JM, Topol EJ, Kander N, O'Neill WW, Walton JA, Ellis SG, Gorman L, Pitt B. Randomized, double blind, placebo-controlled trial of tissue plasminogen activator in unstable angina. J Am Coll Cardiol. 1989;13:434-441.
14. Williams DO, Topol EJ, Califf RM, Roberts R, Mancini J, Joelson JM, Ellis SG, Kleiman NS, and Coinvestigators. Intravenous recombinant tissue-type plasmingen activator in patients with unstable angina pectoris: results of a placebo-controlled, randomized trial. Circulation. 1990;82:376-383.
15. de Zwaan C, Bär FW, Janssen JHA, de Swart HB, Vermeer F, Wellens HJJ. Effects of thrombolytic therapy in unstable angina: clinical and angiographic results. J Am Coll Cardiol. 1988;12: 301-309.
16. Bär FW, Verheugt FWA, Col J, Materne P, Manassier JP, Geslin PG, Metzger J, Raynaud P, Foucault J, de Zwaan C, Vermeer F. Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome: results of the UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplase. Circulation. 1992;86:131-137.
17. Coller BS. Activation affects access to the platelet receptor for adhesive glycoproteins. J Cell Biol. 1986;103:451-456.
18. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest. 1990;86:651-659.
19. 2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood. 1985;66:1456-1459.
20. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueler H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation. 1987;76:142-154.
21. Reiber JHC, Serruys PW, Kooijman CJ, Wijns W, Slager CJ, Gerbrands JJ, Schuurbiers JCH, den Boer A, Hugenholtz PG. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer assisted quantification of coronary cineangiograms. Circulation. 1985;71:280-288.
22. Crawford DW, Brooks SH, Seizer RH, Brandt R, Beckenbach ES, Blankenhorn DH. Computer densitometry for angiographic assessment of arterial cholesterol contents and gross pathology in human atherosclerosis. J Lab Clin Med. 1977;89:378-392.
23. Serruys PW, Reiber JHC, Wijns W, van den Brand M, Kooijman CJ, ten Katen HJ, Hugenholtz PG. Assessment of percutaneous transluminal angioplasty by quantitative coronary angiography: diameter versus densitometric area measurement. Am J Cardiol. 1984;54:482-488.
24. Dellborg M, Riha M, Swedberg K. Dynamic QRS- and ST-segment changes in myocardial infarction monitored by continuous on-line vectorcardiography. J Electrocardiol. 1991;23(suppl):11-19.
25. Rao TK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML, for the TIMI Investigators. Thrombolysis in myocardial infarction (TIMI) trial, phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
26. Landefeld LS, Cook EF, Hatley M. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1987;82:703-713.
27. Wallentin LC, and the Research Group in Instability in Coronary Artery Disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol. 1991;18: 1587-1593.
28. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina: relation to timing of angiography and in-hospital events. Circulation. 1989;80:17-23.
29. Capone G, Wolf NM, Meyer B, Meister SG. Frequency of intracoronary filling defects by angiography in angina pectoris at rest. Am J Cardiol. 1985;56:403-406.
30. Kleiman NS, Ohman ME, Califf RM, George B, Kereiakes D, Aguirre T, Bates E, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: results of the TAMI 8 pilot study. J Am Coll Cardiol. 1993;22:381-389.
31. Kleiman NS. Evaluation of IIb/IIIa platelet receptor antagonist (7E3) in preventing ischemic complications (EPIC). Presented at the American College of Cardiology Annual Meeting, Anaheim, Calif, March 14-18, 1993.
32. Jordan RE, Knight DM, Wagner C, McAber MF, McDonough M, Mattios JA, Coller BS, Weisman HF, Ghrayeb J. A dramatic reduction of the immunogenicity of the anti-GPIIb/IIIa monoclonal antibody 7E3 Fab by humanization of the murine constant domains. Circulation. 1992;86(suppl I):I-411. Abstract.